이스라엘 - 히브리어 - Ministry of Health

teva pharmaceutical indust.ltd - escitalopram as oxalate 20 mg - tablets - escitalopram - treatment of depression.treatment of panic disorder. treatment of generalized anxiety disorder (gad).treatment of social anxiety disorder ( social phobia).treatment of obsessive - compulsive disorder.

이스라엘 - 히브리어 - Ministry of Health

unipharm ltd - escitalopram as oxalate 15 mg - film coated tablets - escitalopram - treatment of depression and panic disorder. treatment of generalized anxiety disorder (gad), treatment of social anxiety disorder (social phobia). treatment of obsessive compulsive disorder.

이스라엘 - 히브리어 - Ministry of Health

medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 300 u/vial - botulinum toxin

이스라엘 - 히브리어 - Ministry of Health

medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 500 u/vial - botulinum toxin

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 100 mg - abrocitinib

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 200 mg - abrocitinib

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 50 mg - abrocitinib

이스라엘 - 히브리어 - Ministry of Health

sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

이스라엘 - 히브리어 - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

이스라엘 - 히브리어 - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob